The France Radiopharmaceuticals Market is a quickly expanding, specialized company with an estimated market value of EUR8.4 billion in 2020. Radiopharmaceuticals are drugs which contain radioactive aspects and have both analysis and also healing abilities. These medications are used primarily to detect different conditions in the body, such as diagnosing cancer cells. The most usual kinds of radiopharmaceuticals utilized in France are Technetium-99m, Fluorine-18, Iodine I, Gallium-68, as well as others. The radiopharmaceuticals market is categorized into applications (cancer cells, cardiology, as well as others), kind (diagnostic/therapeutic), and also end individual (hospitals/clinics clinical imaging centers, and others).
The development of the France radiopharmaceuticals market is mainly driven by the rising prevalence of cancer cells and also cardiology, as well as technological improvements in the health care field. Additionally, the boosting demand for cost-efficient and also specific medical diagnosis and the boosting number of public and personal financial investments in medical imaging are important elements driving the market. Additionally, the rising need for nuclear medicine procedures with radiopharmaceuticals is developing market growth opportunities.
The France radiopharmaceuticals market is dealing with restrictions such as the high cost of scientific tests, trade obstacles, and also financial restraints. Additionally, the demand for radiation safety measures and operational restrictions are hindering the development of the France radiopharmaceuticals market.
With the assistance of brand-new modern technologies, the radiopharmaceuticals market is being changed. Because of this, the advancement of brand-new radiopharmaceutical representatives are becoming extra cost-efficient and also efficient. Additionally, many brand-new innovations are taking place in the health care sector such as individualized medicine as well as the enhancing demand for innovative imaging methods. All of this is producing market possibilities.
The affordable rivalry is solid in the France radiopharmaceuticals market because of the expanding variety of players, along with the presence of international business. The negotiating power of consumers is additionally high as there is a vast array of services and products readily available. There is also excellent bargaining power from distributors as a result of minority resources offered for manufacturing as well as the visibility of strong players out there. The risk from replacements is moderate as the primary use of radiopharmaceuticals is for analysis and therapeutic functions in the healthcare industry. There is additionally modest risk from brand-new participants as the expense of entrance is fairly high due to the high rate of examinations, scientific trials, and regulative approvals.
The future of the France radiopharmaceuticals market is expected to be driven by the raising number of federal government efforts such as the introduction of health care infrastructures, promotional activities, aids, and also initiatives to lower management costs. Additionally, the growing R&D in the pharma market and also technological improvements are expected to fuel the market development. New growths in the distribution of medicine, such as oral and also inhalation types, will produce a lot more opportunities for radiopharmaceuticals. Furthermore, there is enhancing need for individualized medications and also the introduction of artificial intelligence and also machine learning in healthcare is likewise driving the market.
The France radiopharmaceuticals market has great possible for growth as a result of the increasing number of medical trials, the accessibility of innovative techniques, and also the inexpensive of manufacturing. Furthermore, the rising awareness of radiopharmaceuticals, the expanding number of healthcare infrastructures, and also the raising need for personalized medications are developing brand-new development possibilities. Additionally, the fostering of polymerase chain reaction (PCR)- based nucleic acid testing is positioned to sustain the market in the future.
The regulating bodies such as HAS, ANSM, MRT as well as Cerba has laid out strict guidelines on the manufacturing as well as use of radiopharmaceuticals in France. The regulations remain in area to ensure the quality as well as safety and security of the radiopharmaceuticals produced as well as to guarantee the risk-free circulation and disposal of the radioactive waste. In addition, the license charges as well as scientific trial guidelines additionally require to be complied with it.
The France radiopharmaceuticals market is additional segmented based upon radioisotope (Technetium-99m, Fluorine-18, Iodine-I, Gallium-68, Others), application (Cancer cells, Cardiology, Others), kind (Diagnostic, Healing) and also end customers (Hospitals/Clinics, Medical Imaging Centers, Others). The most commonly made use of radioisotope for radiopharmaceuticals in France is Technetium-99m and the primary end-user section is health centers as well as facilities.
The development of the France radiopharmaceuticals market is mainly driven by the rising prevalence of cancer cells and also cardiology, as well as technological improvements in the health care field. Additionally, the boosting demand for cost-efficient and also specific medical diagnosis and the boosting number of public and personal financial investments in medical imaging are important elements driving the market. Additionally, the rising need for nuclear medicine procedures with radiopharmaceuticals is developing market growth opportunities.
The France radiopharmaceuticals market is dealing with restrictions such as the high cost of scientific tests, trade obstacles, and also financial restraints. Additionally, the demand for radiation safety measures and operational restrictions are hindering the development of the France radiopharmaceuticals market.
With the assistance of brand-new modern technologies, the radiopharmaceuticals market is being changed. Because of this, the advancement of brand-new radiopharmaceutical representatives are becoming extra cost-efficient and also efficient. Additionally, many brand-new innovations are taking place in the health care sector such as individualized medicine as well as the enhancing demand for innovative imaging methods. All of this is producing market possibilities.
The affordable rivalry is solid in the France radiopharmaceuticals market because of the expanding variety of players, along with the presence of international business. The negotiating power of consumers is additionally high as there is a vast array of services and products readily available. There is also excellent bargaining power from distributors as a result of minority resources offered for manufacturing as well as the visibility of strong players out there. The risk from replacements is moderate as the primary use of radiopharmaceuticals is for analysis and therapeutic functions in the healthcare industry. There is additionally modest risk from brand-new participants as the expense of entrance is fairly high due to the high rate of examinations, scientific trials, and regulative approvals.
The future of the France radiopharmaceuticals market is expected to be driven by the raising number of federal government efforts such as the introduction of health care infrastructures, promotional activities, aids, and also initiatives to lower management costs. Additionally, the growing R&D in the pharma market and also technological improvements are expected to fuel the market development. New growths in the distribution of medicine, such as oral and also inhalation types, will produce a lot more opportunities for radiopharmaceuticals. Furthermore, there is enhancing need for individualized medications and also the introduction of artificial intelligence and also machine learning in healthcare is likewise driving the market.
The France radiopharmaceuticals market has great possible for growth as a result of the increasing number of medical trials, the accessibility of innovative techniques, and also the inexpensive of manufacturing. Furthermore, the rising awareness of radiopharmaceuticals, the expanding number of healthcare infrastructures, and also the raising need for personalized medications are developing brand-new development possibilities. Additionally, the fostering of polymerase chain reaction (PCR)- based nucleic acid testing is positioned to sustain the market in the future.
The regulating bodies such as HAS, ANSM, MRT as well as Cerba has laid out strict guidelines on the manufacturing as well as use of radiopharmaceuticals in France. The regulations remain in area to ensure the quality as well as safety and security of the radiopharmaceuticals produced as well as to guarantee the risk-free circulation and disposal of the radioactive waste. In addition, the license charges as well as scientific trial guidelines additionally require to be complied with it.
The France radiopharmaceuticals market is additional segmented based upon radioisotope (Technetium-99m, Fluorine-18, Iodine-I, Gallium-68, Others), application (Cancer cells, Cardiology, Others), kind (Diagnostic, Healing) and also end customers (Hospitals/Clinics, Medical Imaging Centers, Others). The most commonly made use of radioisotope for radiopharmaceuticals in France is Technetium-99m and the primary end-user section is health centers as well as facilities.
Key Benefits For Stakeholders
- Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.
- Analyze the key strategies adopted by major market players in france radiopharmaceuticals market.
- Assess and rank the top factors that are expected to affect the growth of france radiopharmaceuticals market.
- Top Player positioning provides a clear understanding of the present position of market players.
- Identify key investment pockets for various offerings in the market.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- New Product Development/ Product Matrix of Key Players
- Patient/epidemiology data at country, region, global level
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
- SWOT Analysis
Key Market Segments
By Type
- Diagnostic
- Therapeutic
By End User
- Hospitals and clinics
- Medical Imaging centers
- Others
By Radioisotope
- Fluorine 18
- Iodine I
- Gallium 68
- Others
- Technetium 99m
By Application
- Cancer
- Cardiology
- Others
- Key Market Players
- Progenics Pharmaceuticals
- Bracco Diagnostics
- Covidien
- Jubilant Pharma
- IBA Molecular
- Curium Pharma
- GE Healthcare
- Cardinal Health
- Novartis
- Lantheus Medical Imaging
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: FRANCE RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE
CHAPTER 5: FRANCE RADIOPHARMACEUTICALS MARKET, BY APPLICATION
CHAPTER 6: FRANCE RADIOPHARMACEUTICALS MARKET, BY TYPE
CHAPTER 7: FRANCE RADIOPHARMACEUTICALS MARKET, BY END USER
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Companies Mentioned
- Progenics Pharmaceuticals
- Bracco Diagnostics
- Covidien
- Jubilant Pharma
- IBA Molecular
- Curium Pharma
- GE Healthcare
- Cardinal Health
- Novartis
- Lantheus Medical Imaging
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
